This site is intended for Healthcare professionals only.

Dr Reddy’s Laboratories Launches Lamotrigine Orally Disintegrating Tablets in US Market


Dr Reddy’s Laboratories Launches Lamotrigine Orally Disintegrating Tablets in US Market

Hyderabad : Dr. Reddy’s Laboratories Ltd.announced that it has launched Lamotrigine Orally Disintegrating Tablets in 25 mg, 50 mg, 100 mg, and 200 mg, a therapeutic equivalent generic version of Lamictal® ODT (lamotrigine) Orally Disintegrating Tablets in the United States market approved by the U.S. Food & Drug Administration (USFDA).

The Lamictal® ODT brand and generic had U.S. sales of approximately $65.5 million MAT for the most recent twelve months ending in July 2016 according to IMS Health*.

Dr. Reddy’s Lamotrigine Orally Disintegrating Tablets 25 mg, 50 mg, 100 mg, and 200 mg are available in bottle count sizes of 30s.

Lamictal® ODT is a registered trademark of GSK group of companies.

*IMS National Sales Perspective: Retail and Non-Retail MAT July 2016

RDY-0916-131



Source: Press Release
0 comment(s) on Dr Reddy’s Laboratories Launches Lamotrigine Orally Disintegrating Tablets in US Market

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted